HyBryte™ treatment results to be presented

Soligenix, Inc. will present results from its HyBryte™ treatment at the US Cutaneous Lymphoma Consortium Annual Workshop 2026. Soligenix, a biopharmaceutical company, is focused on developing and commercializing therapies for significant unmet medical needs. The presentation of HyBryte™ data at this specialized workshop is expected to provide valuable insights into the treatment's efficacy and potential applications in cutaneous lymphoma. This event offers a platform to share clinical findings with experts in the field.